Wall Street Zen Downgrades Lunai Bioworks (NASDAQ:LNAI) to Sell

Posted by Tyrone Williams on Feb 22nd, 2026

Lunai Bioworks (NASDAQ:LNAI – Get Free Report) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Lunai Bioworks in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Check Out Our Latest Stock Analysis on LNAI

Lunai Bioworks Trading Down 5.5%

Lunai Bioworks stock opened at $0.55 on Friday. The firm has a 50 day moving average price of $0.87. Lunai Bioworks has a 12 month low of $0.52 and a 12 month high of $14.00. The stock has a market capitalization of $13.19 million, a P/E ratio of -7.79 and a beta of 0.46.

Lunai Bioworks (NASDAQ:LNAI – Get Free Report) last issued its earnings results on Tuesday, February 17th. The company reported ($0.08) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lunai Bioworks stock. Millennium Management LLC purchased a new position in Lunai Bioworks Inc. (NASDAQ:LNAI – Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned approximately 0.87% of Lunai Bioworks at the end of the most recent quarter. 71.41% of the stock is owned by institutional investors and hedge funds.

Lunai Bioworks Company Profile

(Get Free Report)

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.